Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
8.65
-0.85 (-8.95%)
At close: May 13, 2025, 4:00 PM
8.65
0.00 (0.00%)
Pre-market: May 14, 2025, 5:02 AM EDT
Upstream Bio Employees
Upstream Bio had 52 employees as of December 31, 2024.
Employees
52
Change
n/a
Growth
n/a
Revenue / Employee
$44,154
Profits / Employee
-$1,724,135
Market Cap
465.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
UPB News
- 8 days ago - Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs - GlobeNewsWire
- 26 days ago - Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent - Seeking Alpha
- 6 weeks ago - 3 Dividend Giants To Buy As Tariffs Hit Stocks - Benzinga
- 2 months ago - Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Upstream Bio to Present at Upcoming March Investor Conferences - GlobeNewsWire
- 5 months ago - Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation - Seeking Alpha
- 5 months ago - Upstream Bio Announces Addition to Russell 2000® Index - GlobeNewsWire
- 6 months ago - Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say - Benzinga